Get the Stockscreener App
18.52
0.86%
-0.16
After Hours:
18.52
Takeda Pharmaceutical Co Adr stock is traded at $18.52, with a volume of 2.67M.
It is down -0.86% in the last 24 hours and up +1.42% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
See More
Previous Close:
$18.68
Open:
$18.73
24h Volume:
2.67M
Relative Volume:
1.04
Market Cap:
$59.16B
Revenue:
$29.91B
Net Income/Loss:
$1.30B
P/E Ratio:
45.66
EPS:
0.4056
Net Cash Flow:
$3.49B
1W Performance:
+2.32%
1M Performance:
+1.42%
6M Performance:
+3.93%
1Y Performance:
+34.99%
1-Day Range:
$18.52
$18.82
1-Week Range:
$18.14
$18.82
52-Week Range:
$12.99
$19.10
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.52 | 59.16B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.25 | 48.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.44 | 41.51B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.30 | 30.70B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
543.40 | 23.31B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-13-26 | Resumed | Morgan Stanley | Overweight |
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
AI in Drug Discovery Market Poised for Rapid Growth Through 2035, Fueled by Faster R&D, Precision Medicine and Rising Biopharma Investment - GlobeNewswire Inc.
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - GlobeNewswire Inc.
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Takeda stock advances after U.S. FDA clears MIMRYLO cancer drug - AD HOC NEWS
Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - valueresearchonline.com
Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed ToneBlock Trade Flow - vinanet.vn
Corporate Lobbying Dashboard - Quiver Quantitative
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance LevelBPI Bull Correction - vinanet.vn
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes - GlobeNewswire Inc.
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Nigeria
6 High-Yield International Dividend Stocks Analysts Love - Forbes
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Options - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Takeda Pharmaceutical Co Adr Stock (TAK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lauren Rusckowski Duprey | Chief Transformation Officer |
Sep 10 '26 |
Proposed Sale |
18.37 |
34,535 |
634,408 |
0 |
| Plump Andrew Stewart | President, R&D |
Sep 02 '26 |
Sale |
18.49 |
116,191 |
2,148,372 |
145,465 |
| Plump Andrew Stewart | Officer |
Sep 02 '26 |
Proposed Sale |
18.49 |
116,191 |
2,148,372 |
0 |
| Plump Andrew Stewart | President, R&D |
Aug 19 '26 |
Sale |
18.49 |
19,651 |
363,347 |
261,656 |
| Plump Andrew Stewart | Officer |
Aug 19 '26 |
Proposed Sale |
18.49 |
19,651 |
363,348 |
0 |
| Greenway Nicola Deidre Petal | Chief Human Resources Officer |
Aug 18 '26 |
Sale |
18.11 |
12,980 |
235,118 |
40,049 |
| Nicola Greenway | Chief Human Resources Officer |
Aug 14 '26 |
Proposed Sale |
17.39 |
12,980 |
225,722 |
0 |
| Shannon Elaine Mary | Pres., Global Supply & Quality |
Aug 11 '26 |
Sale |
17.55 |
20,363 |
357,371 |
67,311 |
| Elaine Shannon | President, Global Supply & Qua |
Aug 11 '26 |
Proposed Sale |
17.45 |
20,363 |
355,334 |
0 |
| Pacheco Rhonda Janice | President, U.S. Business Unit |
Aug 10 '26 |
Sale |
17.10 |
16,901 |
289,007 |
182,507 |
0.19%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):